APH 0.00% 17.0¢ australian primary hemp limited

cheapest biotech stock on asx

  1. 92 Posts.
    Neuren is significant undervalued ..

    Neuren Pharma ( NEU.AX)
    Marketcap: only 48 million A$
    Price: 0,34 A$

    Awesome Pipeline :

    Glypromate MCI in CABG Phase 3 ongoing
    NNZ-2566 Severe TBI (traumatic brain injury) Phase 2a (deal with US Army)
    NNZ-2566 Mild/Mod TBI Phase 2
    Motiva Post-stroke-Apathy Phase 2b

    Taylor Collison
    http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf

    By the end 1Q CY08, we expect Neuren to be running four major
    efficacy trials; namely three Phase 2 trials for NNZ-2566 in
    mild/moderate and severe TBI and Motiva™ in post stroke abulia/
    depression coupled with the current Phase 3 trial for Glypromate® in
    CABG. All indications potentially provide Neuren with first to market,
    billion dollar opportunities. With a current market cap of $40.2m, Neuren
    remains a solid value proposition in the sector, where FDA INDs for mid
    to late stage clinical trials continues to remain a vexing proposition. We
    maintain our Speculative Buy recommendation and price target of $1.30,
    though expect to make changes to our valuation model once the
    acquisition has closed, which we expect during the current Q.
 
watchlist Created with Sketch. Add APH (ASX) to my watchlist
(20min delay)
Last
17.0¢
Change
0.000(0.00%)
Mkt cap ! $11.85M
Open High Low Value Volume
17.0¢ 17.0¢ 17.0¢ $7.336K 43.15K

Buyers (Bids)

No. Vol. Price($)
4 104988 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
17.5¢ 9090 1
View Market Depth
Last trade - 15.02pm 29/09/2020 (20 minute delay) ?
APH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.